

Oncology Clinical Pathways Waldenstrom Macroglobulinemia/ Lymphoplasmacytic Lymphoma

May 2024 – V1.2024



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Table of Contents

Presumptive Conditions	3
Waldenstrom Macroglobulemia/Lymphoplasmacytic Lymphoma	4
Waldenstrom Macroglobulemia/Lymphoplasmacytic Lymphoma, Relapsed	5
Waldenstrom Macroglobulemia/Lymphoplasmacytic Lymphoma, Multiply Relapsed	6
Waldenstrom Macroglobulemia/Lymphoplasmacytic Lymphoma – Molecular Testing Table	7



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma – Presumptive Conditions

VA automatically presumes that certain disabilities were caused by military service. This is because of the unique circumstances of a specific Veteran's military service. If a presumed condition is diagnosed in a Veteran within a certain group, they can be awarded disability compensation.

Atomic Veterans – Exposure to Ionizing Radiation

- Lymphomas, other than Hodgkin's disease

Vietnam Veterans – Agent Orange Exposure or Specified Locations

- Non-Hodgkin's lymphoma

Gulf War and Post 9/11 Veterans


If the patient served on or after Sept. 11, 2001, in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen or if the patient served in the *Southwest Asia theater of operations, or Somalia, on or after Aug. 2, 1990, specific conditions include:

- Lymphoma of any type

* The Southwest Asia theater of operations refers to Iraq, Kuwait, Saudi Arabia, the neutral zone between Iraq and Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, Oman, the Gulf of Aden, the Gulf of Oman, the Persian Gulf, the Arabian Sea, the Red Sea, and the airspace above these locations.

For more information, please visit [U.S. Department of Veterans Affairs - Presumptive Disability Benefits \(va.gov\)](https://www.va.gov/presumptive-disability-benefits/)

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

^a **Diagnosis** IgM monoclonal gammopathy in the serum, bone marrow biopsy and/or lymph node biopsy showing infiltration with lymphoplasmacytic cells; the presence of MYD88 mutations are supportive but not diagnostic; in MYD88 mutated LPL, CXCR4 mutations confer a negative prognosis; if MYD88 is not present

^b **Workup Evaluation** CBC diff, HIV, hepatitis B and C testing, LDH/uric acid, CT scans of the chest/abdomen/pelvis, quantitative immunoglobulins, comprehensive metabolic profile, serum protein electrophoresis with immunofixation


^c **Indications for Treatment** anemia, bleeding, hyperviscosity, symptomatic adenopathy or organomegaly, peripheral neuropathy directly related to Waldenstrom

^d **Symptoms Related to Hyperviscosity** require urgent plasmapheresis followed by systemic therapy

^e **Rituximab** causes a transient increase in IgM levels within a few days of the first infusion and therefore should not be used in patients with symptoms of hyperviscosity; plasmapheresis can be utilized to treat the IgM flare if symptoms of hyperviscosity develop

^f **Other Symptoms** bulky lymphadenopathy, hemoglobin <10 g/dL, hyperviscosity (after plasmapheresis), constitutional symptoms, IgM-related peripheral neuropathy

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma, Relapsed



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

^a **Indications for Treatment** anemia, bleeding, hyperviscosity, symptomatic adenopathy or organomegaly, peripheral neuropathy directly related to Waldenstrom's


^b **Rituximab** causes a transient increase in IgM levels within a few days of the first infusion and therefore should not be used in patients with symptoms of hyperviscosity; plasmapheresis can be utilized to treat the IgM flare if symptoms of hyperviscosity develop

^c **Zanubrutinib** not indicated in MYD88 wild type

^d **Chemoimmunotherapy** examples include bendamustine,+ rituximab, cyclophosphamide

BTK Bruton Tyrosine Kinase

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma, Multiply Relapsed



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

^a **Indications for Treatment** anemia, bleeding, hyperviscosity, symptomatic adenopathy or organomegaly, peripheral neuropathy directly related to Waldenstrom

^b **Refer to Cell Therapy** if considered an appropriate cell therapy candidate

BTK Bruton Tyrosine Kinase

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Molecular Testing Table

Eligibility	Test Category	Test Type	Recommended Vendors	NPOP Coverage	Specimen Type
Lymphoplasmacytic Lymphoma*	Molecular Testing	Targeted sequencing for MYD88 and CXCR4 mutations	Local VA or locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood

* Karyotype and FISH are not informative